Hinge Health director-linked funds sell 11K shares

Funds associated with Hinge Health director Robinson Elliott sold HNGE Class A shares at a weighted average of $92.37 on September 9, 2026.

Rhea-AI Filing Summary

Hinge Health, Inc. (HNGE) reported that investment funds associated with director Robinson Elliott sold shares of its Class A Common Stock on September 9, 2026.

Bessemer Venture Partners X L.P. sold 5,489 shares and Bessemer Venture Partners X Institutional L.P. sold 5,848 shares at a weighted average price of $92.37, in multiple trades between $92.00 and $92.69. Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in these shares and disclaims beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

Sale: 0 shares

Sale 1 txn

Insider Robinson Elliott

Role Director

Sold 0 shs ($0.00)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	0	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 0 shares (Indirect, See footnote)

Footnotes (2)

1. F1. On September 9, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 5,489 and 5,848 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.37. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.69. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
2. F2. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

Key Figures

Shares sold by Bessemer Venture Partners X L.P.: 5,489 shares Shares sold by Bessemer Venture Partners X Institutional L.P.: 5,848 shares Weighted average sale price: $92.37 per share +1 more

4 metrics

Shares sold by Bessemer Venture Partners X L.P. 5,489 shares Class A Common Stock sales of Hinge Health, Inc. on September 9, 2026

Shares sold by Bessemer Venture Partners X Institutional L.P. 5,848 shares Class A Common Stock sales of Hinge Health, Inc. on September 9, 2026

Weighted average sale price $92.37 per share Aggregate price for the Bessemer Funds’ HNGE Class A sales

Sale price range $92.00–$92.69 per share Prices at which HNGE Class A shares were sold on September 9, 2026

Key Terms

weighted average price, indirect, passive economic interest, beneficial ownership, pecuniary interest

4 terms

weighted average price financial

"at a weighted average price of $92.37"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect, passive economic interest financial

"has an indirect, passive economic interest in the shares"

beneficial ownership financial

"disclaims beneficial ownership of the securities held by the Bessemer Funds"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest, if any, in such securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider-related share sales in HNGE were reported on September 9, 2026?

Funds associated with director Robinson Elliott sold Hinge Health Class A shares on September 9, 2026, including 5,489 shares by Bessemer Venture Partners X L.P. and 5,848 shares by Bessemer Venture Partners X Institutional L.P.

At what prices were the HNGE shares sold by the Bessemer funds?

The Bessemer funds sold HNGE shares at a weighted average price of $92.37, executed in multiple transactions at prices ranging from $92.00 to $92.69 per share.

Does director Robinson Elliott directly own the HNGE shares sold in this Form 4?

No. The shares are held by Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. Elliott has an indirect, passive economic interest and disclaims beneficial ownership except for any pecuniary interest.

Were the September 9, 2026 HNGE sales under a Rule 10b5-1 trading plan?

The filing indicates that no Rule 10b5-1 trading plan is reported for these transactions; the document-level 10b5-1 checkbox is not marked as being under a plan.

Who are the entities selling HNGE shares in connection with director Robinson Elliott?

The selling entities are Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P., together referred to as the Bessemer Funds, in which Elliott has an indirect interest through related partnership entities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 06:50 PM Accepted by SEC EDGAR 09/11/2026 - 06:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson Elliott

(Last) (First) (Middle)

C/O BESSEMER VENTURE PARTNERS

1865 PALMER AVENUE, SUITE 104

(Street)

LARCHMONT NEW YORK 10538

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/09/2026		S		0(1)	D	$0	0	I	See footnote(1)(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 9, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 5,489 and 5,848 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.37. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.69. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

	/s/ Augie Wilkinson, Attorney-in-Fact	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)